Tag Archives: LSN

Hot Investor Mandate 2: Company Acquired by Chinese Pharma Seeks Early to Mid-Stage Therapeutics Partnering Opportunities, Capable of Investing Up to $100M

17 May

A spin-out pharmaceutical company recently acquired by a Chinese pharmaceutical company is seeking early to mid-stage technology for equity, in-licensing, and acquisition opportunities, and typically invests $10M to $100M per project depending on the opportunity. In the past several years, the company also acquired two USA companies at $200-300M range. The company is seeking opportunities on a global level.

The firm is interested in early to mid-stage therapeutics in inflammatory diseases, cardiovascular diseases, diabetes, and cancer. The firm seeks preclinical to clinical stage pharmaceuticals with particular interest in large molecule biologics including naturally derived molecules and fermentation based products.

The firm is open to talking with companies, including virtual organizations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , ,

Hot Investor Mandate 3: California-Based VC Seeking to Invest in Therapeutic Technologies that Solve Problems Within Genetically Driven Diseases

17 May

A California-based firm backed by a number of well-known global funds is actively seeking investment opportunities. The firm prefers to be the first institutional investor in a company, and is typically an active, lead investor (often the sole investor). The firm typically invests in 5 opportunities per year.

The firm focuses on genetic drivers of disease, and therefore only invests in treatments for monogenic diseases or genetically-driven cancers. The firm is only interested in treatments that elicit a disease-modifying response; treatments that target symptoms of monogenic diseases are not of interest. Therapeutics must have a clearly-defined mechanism of action. The firm usually invests at the preclinical stage, up to 18 months prior to IND, but is open to later stage candidates (including clinical).

The firm focuses on individual products, not technology platforms. The firm typically houses each single asset in its own discrete subsidiary. The firm has internal expertise in medicinal chemistry, biology, and clinical trials, with personnel having significantly contributed to 30+ INDs and 10+ approved drugs. The company will often leverage internal expertise for subsidiaries, and can also assist with recruiting.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: Chinese VC/PE Firm Works on Early and Late-Stage Deals in Medical Devices and Therapeutics with China Market Potential

17 May

A Shanghai-based venture capital/private equity firm manages both USD and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid-development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

Hot Investor Mandate 1: Family Office Creates Investment Arm for Medical Device Companies Based in the U.S.

10 May

A family office arm specializes in investing in and operating medical device companies in which it holds a controlling interest. The firm looks to invest in early and seed stage companies with the goal of investing in 1-2 companies per year to add to its portfolio.

The firm looks to invest in medical device companies that are still in development. The firm prefers technologies subject to the FDA 510(k) pathway, but will consider PMA/combination device and therapeutics if the technology is extremely disruptive. The investors are agnostic with regards to subsector and indication. Current portfolio companies include surgical tools for cardiovascular interventions, consumer health electronics, hospital hardware and therapeutic delivery devices for multiple clinical applications.

The firm looks to invest in companies with great technology that need operational expertise to help advance the technology to market with the goal of leveraging its internal management team for execution of product development, regulatory, and commercial strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , ,

Hot Investor Mandate 2: Venture Firm Seeking Cellular Engineering Technologies for Diagnostics, Devices, and Therapeutics

10 May

A venture fund focusing on the frontiers of the intersection of science and technology looks for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

Hot Investor Mandate 3: San Francisco-based Large Global Private Investment Firm Seeking Early-Stage Therapeutics and Commercial-Stage Devices Worldwide

10 May

A large PE/VC is investing in life science innovation through its $5B Growth and Rise funds. The firm is a leading global private investment firm with over $59 billion AUM, based in San Francisco, California. The investment size typically ranges from $20M to $50M in equity. The firm is agnostic to company location or stage.

The firm aims to invest in therapeutics, commercial stage medical devices, and opportunistically in other innovative life sciences spaces. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: Hong Kong-based Family Office Seeking Small Molecule Therapeutics, Devices, Diagnostics, and Healthcare IT Globally

10 May

A wholly-owned venture arm of a Hong-Kong based family is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , ,

← Older Entries
Newer Entries →